Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
- Nov 17, 2016Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting- Complete results of Phase 1/2 CHRYSALIS trial of gilteritinib in patients with Relapsed/Refractory AML to be presented during Oral Session on Dec. 5 -
- Nov 8, 2016Astellas, Donate Life America and World Transplant Games Federation Celebrate Achievements for Global Transplant Community at History-making Rugby Match
- Nov 2, 2016Doug Noland will serve as Executive Director
- Oct 28, 2016- Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -
- Oct 27, 2016Astellas and Donate Life America Attempt to Achieve GUINNESS WORLD RECORDS™ Title for Organ Donor Registrations-Social Shares of #OrganDonor Support $5 Contribution from Astellas to World Transplant Games Federation, up to $175,000 USD-
- Oct 21, 2016FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer- TERRAIN Trial Showed Improved Radiographic Progression-Free Survival with Enzalutamide Versus Bicalutamide in Men with Metastatic Castration-Resistant Prostate Cancer -
- Oct 20, 2016Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand ActivitySponsors CNN Heroes Starting October 20